Skip to content
About
Menu Toggle
Overview
Team
Board of Directors
Careers
Technology
Menu Toggle
Overview
Antigen Design
Antibody Generation
Menu Toggle
OmniRat
OmniMouse
OmniChicken
Omni
dAb
OmniTaur
Bispecific Platforms
Screening
Menu Toggle
GEM
xPloration
Antibody Optimization
Menu Toggle
Fc-Silencing Technology
Ion Channel and Transporter Technology
In Silico Technologies
Scientific Publications
Partnerships
Menu Toggle
Overview
Why Partner with OmniAb?
Partner Pipeline
Contact Business Development
Investors
Menu Toggle
Overview
News
Events & Presentations
Stock Info
SEC Filings
Governance
Menu Toggle
Governance Documents
Executive Officers
Board of Directors
Board Committees
Resources
Menu Toggle
Investor FAQs
Information Request Form
Investor Email Alerts
Investor Contacts
Contact
Main Menu
About
Menu Toggle
Overview
Team
Board of Directors
Careers
Technology
Menu Toggle
Overview
Antigen Design
Antibody Generation
Menu Toggle
OmniRat
OmniMouse
OmniChicken
Omni
dAb
OmniTaur
Bispecific Platforms
Screening
Menu Toggle
GEM
xPloration
Antibody Optimization
Menu Toggle
Fc-Silencing Technology
Ion Channel and Transporter Technology
In Silico Technologies
Scientific Publications
Partnerships
Menu Toggle
Overview
Why Partner with OmniAb?
Partner Pipeline
Contact Business Development
Investors
Menu Toggle
Overview
News
Events & Presentations
Stock Info
SEC Filings
Governance
Menu Toggle
Governance Documents
Executive Officers
Board of Directors
Board Committees
Resources
Menu Toggle
Investor FAQs
Information Request Form
Investor Email Alerts
Investor Contacts
Contact
Teva TEV-53408
January 24, 2022
March 20, 2024
Post navigation
←
Previous Post
Next Post
→
